A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera� in patients with CD20-positive B-cell non-Hodgkin lymphoma

Xiaohong Han, Mingzhi Zhang, Huaqing Wang, Qingyuan Zhang, Wei Li, Miao-Wang Hao, Yuhuan Gao, Jie Jin, Hanyun Ren, Yun Tang, Xiaonan Hong, Xiaoyan Ke, Hang Su, Lin Gui, Jianmin Luo, Liangzhi Xie, Wenlin Gai, Yuankai ShiChinese 2022 · DOI

Abstract

In this study, the PK, PD, immunogenicity, and safety profile of ripertamab (SCT400) were similar to rituximab (MabThera<sup>®</sup>) in Chinese patients with CD20-positive B-cell NHL.
BibTeX
@inproceedings{han2022multi,
  author = {Xiaohong Han and Mingzhi Zhang and Huaqing Wang and Qingyuan Zhang and Wei Li and Miao-Wang Hao and Yuhuan Gao and Jie Jin and Hanyun Ren and Yun Tang and Xiaonan Hong and Xiaoyan Ke and Hang Su and Lin Gui and Jianmin Luo and Liangzhi Xie and Wenlin Gai and Yuankai Shi},
  title = {{A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera� in patients with CD20-positive B-cell non-Hodgkin lymphoma}},
  booktitle = {Chinese},
  year = {2022},
  doi = {10.21147/j.issn.1000-9604.2022.06.08},
}

Loading related content...

Figure